Navigation Links
Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
Date:6/9/2008

n on schedule to initiate our second AZ-004 Phase 3 study during the third quarter of this year."

AZ-004 Phase 3 Clinical Trial Design

The first AZ-004 Phase 3 clinical trial enrolled 344 patients with schizophrenia at 24 U.S. clinical centers. The trial is an in-clinic, multi-center, randomized, double-blind, placebo-controlled study, testing AZ-004 at two dose levels, 5 and 10 mg. The trial protocol specified that patients were eligible to receive up to 3 doses of study drug in a 24-hour period, depending on their clinical status.

The primary endpoint for the study is the reduction in agitation as measured by the change from baseline in the PEC Score, measured at 2 hours after the first dose. The PEC Score is a commonly used endpoint in acute agitation studies and is the abbreviation for PANSS (Positive and Negative Symptom Scale) Excited Component Score. The trial protocol specified that various assessments of a patient's agitation state be conducted at serial time points using standard agitation scales over the first 4-hour post-dose time period, with follow-up assessments at the end of the 24-hour study period. Side effects were recorded throughout the 24-hour period.

Alexza projects that the initial results will be reported before the end of September 2008. The second Phase 3 clinical trial is projected to begin in Q3 2008. The design of the second study will be similar to the first trial, except that the patient population will be bipolar disorder patients.

Conference Call Information

The Company will host an investor conference call to discuss today's announcement on Monday, June 9, 2008 at 5:15 p.m. Eastern Time. A replay of the call will be available for two weeks following the event. The conference call, replay and webcast are open to all interested parties.

Domestic callers: 1-800-299-0148

International callers: 1-617-801-9711

Passcode: 11378886

Webcast information:

<
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 According ... Market by Extraction type (SFE, Cold Pressed, Organic ... Care, Pharmaceutical, Food Supplements, Fragrance, & Others) - Global ... defines and segments the Amaranth Seed Oil Market ... size in terms of value. The Amaranth Seed ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... Research and Development Trend Forecast of Pharmaceutical Equipment ... analyzes China,s pharmaceutical equipment industry ... demand, competition landscape, and business performance of domestic major ...
(Date:8/29/2014)... Corporation , a neurodiagnostics medical device company based in ... Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, FRCSEd  was ... " Teo Forcht Dagi is an experienced leader with ... said Remis Bistras , President and CEO of Vittamed. ... entrepreneurial expertise to our Board." Dr. Dagi is ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2
...  In a move aimed at bolstering current systems for assessing ... created a new method that combines multiple forms of widely ... which rely on detecting evidence of drug safety issues as ... may be able to identify issues years in advance. ...
... Systems, Inc. (NASDAQ: DCTH ) appointed Gregory ... "As a widely respected hepatologist and 2011 ... Gores will contribute a wealth of clinical knowledge on ... Advisory Board," said Eamonn P. Hobbs, CEO & President ...
Cached Medicine Technology:Taking a Predictive Approach to Identifying Adverse Drug Reactions 2Taking a Predictive Approach to Identifying Adverse Drug Reactions 3Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board 2Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board 3Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board 4
(Date:8/30/2014)... In today’s world, a good night’s sleep has become especially ... (a medical problem where the airway collapses during sleep and ... rest they need to face their daily challenges. , ... people in the United States alone have sleep apnea. Of ... those treated, many cannot tolerate their prescribed medical device known ...
(Date:8/30/2014)... One of the most recent dietary trends ... diet. Originally meant for sufferers of gluten intolerance and celiac ... who are looking to get healthier by simply consuming foods ... kind of information erroneous, it also exposes those same consumers ... a drastic change in their food consumption habits. ...
(Date:8/30/2014)... The new review published by Daily Gossip ... Karen Brimeyer, who wanted to make her guide accessible to ... is now easy to find in the form of an ... the author of the new method shares all her tips ... writes in its review that the leaky gut syndrome can ...
(Date:8/30/2014)... August 28th, 2014: With the ... society and the toll that takes on the individual ... continuing education for physical therapists addresses this problem. , ... help others, Hands-On Seminars is offering discounts on their ... learning styles are available to fit the individual needs ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 Ms. Meriwether’s striking ... She certainly has an impressive resume to boost. ... USA in 2012. However, she’s also a two time ... student. Nana trained for the 2008 Olympics and played ... USA website, “This six-foot beauty from Potomac, Maryland is a ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:“What is Gluten: Three Things You Need to Know Before Adopting a Gluten-Free Diet” Reveals What Readers Need to Know About the Benefits of a Strict Gluten Diet - Vinamy 2Health News:Leaky Gut Cure Review Reveals Unique Method to Stop Chronic Symptoms 2Health News:Leader in Manual Therapy Continuing Education Makes it Easier for Physical Therapists to Improve Results on Patients 2Health News:NJ Top Dentists Announces Cover Model for the Healthy Living: Top Dentists Issue 2
... , MOUNTAIN VIEW, Calif., Sept. 17 ... of kidney dialysis services and a major sponsor of nephrology ... Foundation,s "Pathway to a Cure" walk event in California,s capital ... 2009 at The Capital Building, 1315 10th Street, Sacramento, CA. ...
... EDGEWATER, Md., Sept. 17 The dialogue ... company sees the issue from a totally different perspective. ... technological readiness to implement healthcare changes. , , ... released "Healthcare: State-of-Readiness for HITECH and EHR (Electronic Health ...
... , , DALLAS, ... families and eyesight, as many schools require eye exams and teachers ... new school year, it,s also a chance for families to kick ... day green habits. With this in mind, today Essilor announced the ...
... - (OTCBB: GVBP.OB) - GENova Biotherapeutics Inc. ("GENova"), ... that disrupt the advance of life-threatening cancers, today ... Beckpharma Ltd. ("Beckpharma") -a pharmaceutical development company also ... are joining forces in their mutual mission to ...
... ... is to manage their own health and fitness. The incredible growth of Max Muscle ... for the safe, natural, and scientifically-backed and proven products that Max Muscle Sports Nutrition has ... ...
... ... Alopecia treatment, the "Invisible" hair system. Produced individually for those with medically caused hair ... touch and can be worn long-term. , ... London, UK (PRWEB) September 17, 2009 -- London-based White Cliffs ...
Cached Medicine News:Health News:Satellite Healthcare Helps Support the Cure for Kidney Disease in Sacramento 2Health News:National Survey Reveals Healthcare Providers' Technological Readiness to Participate in Electronic Health Records Network 2Health News:National Survey Reveals Healthcare Providers' Technological Readiness to Participate in Electronic Health Records Network 3Health News:Back to School Season is Time for New Green Routines 2Health News:Back to School Season is Time for New Green Routines 3Health News:GENova Biotherapeutics secures new cancer drugs targets 2Health News:GENova Biotherapeutics secures new cancer drugs targets 3Health News:Max Muscle Franchising Is Fueled By The Passion Behind The Brand 2Health News:Max Muscle Franchising Is Fueled By The Passion Behind The Brand 3Health News:Advanced Alopecia Treatment developed by London-based Hair Replacement Provider 2Health News:Advanced Alopecia Treatment developed by London-based Hair Replacement Provider 3
MultiWash Advantage is a versatile microplate washer engineered for reliability. It is designed for lab environments to help streamline their daily processes....
Synchron Hemoglobin A1c (HbA1c) utilizes two unique cartridges, Hb and A1c, to determine HbA1c concentration as a percentage of total hemoglobin....
... Monoclonal antibody method for HbA1c provides outstanding ... 99% agreement with the HPLC method(1) , ... a CV of 2.6%* means your results ... (NGSP) certified method, as recommended by the ...
The sole coagulation analyzer in the world that uses a unique dry reagent card....
Medicine Products: